History | |
Initial Contributions of Adamantiades and Behcet | p. 3 |
A Historical Review of Adamantiades-Behcet's Disease | p. 7 |
Epidemiology | |
Multicentre Clinical Registries | p. 17 |
Epidemiology of Behcet's Disease in Asian Countries and Japan | p. 25 |
Recent Epidemiological Data on Behcet's Disease in Iran | p. 31 |
Prevalence of Behcet's Disease among Iraqis | p. 37 |
Current Epidemiological Data from the German Registry of Adamantiades-Behcets Disease | p. 43 |
Heterogenity of Clinical Manifestations in Behcet's Disease among Different Ethnic Groups | p. 49 |
Behcet's Disease in Patients of German and Turkish Origin - A Comparative Study | p. 53 |
Influence of Sex on Patients with Behcet's Disease in Korea | p. 59 |
The Influence of Gender on the Frequency of Clinical Symptoms in Behcet's Disease | p. 65 |
The Influence of Gender on the Severity, and the Outcome of Ocular Lesions in Behcet's Disease | p. 67 |
The Implications of Nonaphthous Beginning of Behcet's Disease | p. 73 |
Clinical Manifestations and Course of 200 Japanese Patients with Behcet's Disease | p. 77 |
Clinical Presentation of Behcet's Disease in Internal Medicine | p. 81 |
The Change of Clinical Manifestations of Patients with Behcet's Disease in Japan | p. 83 |
Chronology of Clinical Manifestations in Behcet's Disease | p. 85 |
General Aspects and Clinical Manifestations of 100 Iraqi Patients with Behcet's Disease | p. 91 |
The Prevalence of Behcet's Syndrome and its Neurological Complications in Hertfordshire, U.K. | p. 95 |
Clinical and Genetic Characteristics of Late-Onset Behcet's Disease | p. 99 |
Diagnostic criteria, prognostic parameters, assessment of disease activity, and quality of life | |
The Importance of the Manifestations Besides the Ones Included in International Criteria for Behcet's Disease | p. 105 |
Influence of Pathergy Test on the Accuracy of Different Diagnosis Criteria for Behcet's Disease | p. 109 |
Measuring Health Related Quality of Life | p. 113 |
Univariate and Multivariate Analyses Comparing Demographic, Genetic, Clinical, and Serological Risk Factors for Severe Adamantiades-Behcet's Disease | p. 123 |
Is Long Term Observation of Patients with Recurrent Aphthous Stomatitis Necessary? | p. 127 |
Acetylator Phenotype in Behcet's Disease | p. 131 |
HLA Antigen, Severity and Acetylator Phenotype in Behcet's Disease Patients with Non-Relative Parents | p. 139 |
Risk Factors of Neuro-Behcet | p. 143 |
Association of HLA-B51 with Clinical Expression of Behcet's Disease | p. 147 |
The Behcet's Disease Activity Index | p. 149 |
Development of Clinical Activity Form for Korean Patients with Behcet's Disease | p. 153 |
Living with Behcet's Disease | p. 157 |
Pathogenesis | |
Pathogenesis of Adamantiades-Behcet's disease | p. 161 |
Immunopathogenesis and Prevention of Uveitis with the Behcet's Disease-Specific Peptide Linked to Cholera Toxin B | p. 173 |
The Role of Infectious Agents in the Pathogenesis of Behcet's Disease | p. 181 |
Detection of Microbial DNA in Skin Lesions from Patients with Behcet's Disease | p. 185 |
Association of Mycoplasma fermentans with Adamantiades-Behcet's Disease | p. 191 |
Antimicrobial Activity of Synthetic Human CAP18 Peptides to Streptococcus sanguis Isolated from Patients with Behcet's Disease | p. 195 |
Anti-Saccharomyces Cerevisiae Antibodies | p. 201 |
Genetics | |
The Human Genome Project: What We have Learnt about the MHC Region on Chromosome 6 and its Potential to Behcet's Disease | p. 207 |
Comparison of Proteome Map Between Sera of Patients with Behcet's Disease and Controls | p. 213 |
HLA Typing for Class I and Class II Antigens in Iraqi Patients with Behcet's Disease (Sporadic and Familial Cases) | p. 217 |
Strong Association of MIC-A*009 of Extracellular Domains and MIC-A*A6 of Transmembrane Domain in Korean Patients with Behcet's Disease | p. 221 |
MICA Transmembrane Region Polymorphism and HLA B51 in Tunisian Behcet's Disease Patients | p. 225 |
HLA-B51 Frequency in Iranian Patients with Behcet's Disease | p. 229 |
Frequency of HLA in Patients with Behcet's Disease and Association with Occlusive Retinal Vasculitis | p. 231 |
The ICAM1469*E is Associated with Susceptibility to Ocular Lesions and Vasculitis in Korean Patients with Behcet's Disease | p. 235 |
Immunology | |
Chemokines in Behcet's Disease, a Field to Be Explored as a Potential Basis for Therapy | p. 239 |
Expression of CCR5 in Behcet's Disease | p. 245 |
Immunophenotype and Th1/Th2 Cytokines in Patients with Adamantiades-Behcet's Disease | p. 249 |
Cytokine Production of Peripheral Blood Mononuclear Cells Stimulated with Streptococcus Sanguis Antigen in Patients with Behcet's Disease | p. 255 |
Serum Levels of Soluble TNF-[alpha] Receptor-II (P75), Circulating [gamma delta] T-Cells and Adamantiades-Behcet's Disease Activity | p. 261 |
T-[gamma delta] Receptor Restriction in Peripheral Lymphocytes of Patients with Behcet's Disease | p. 267 |
Lymphocyte Subsets and Activated Neutrophils in Iraqi Patients with Behcet's Disease | p. 269 |
L-Selectin Expression on Leukocytes of Patients with Behcet's Disease | p. 273 |
Autoimmunity to S-Antigen and Retinal Vasculitis in Patients with Behcet's Disease | p. 279 |
Nerve Growth Factor in Behcet's Disease | p. 283 |
Low Serum Mannose-Binding Lectin Levels in Behcet's Disease | p. 287 |
Concepts for Research | |
ISBD Basic Research Perspectives | p. 293 |
Mucocutaneous manifestations | |
Complex Aphthosis: Evaluation for Behcet's Disease? | p. 303 |
Complex Aphthosis | p. 311 |
Comparison of Oral Aphthae in Behcet's Disease and Idiopathic Recurrent Aphthous Stomatitis | p. 317 |
Bipolar Aphthosis. A Forme Fruste of Behcet's Disease | p. 321 |
The Effect of Smoking on the Clinical Features of Adamantiades-Behcet's Disease | p. 323 |
Muco-Cutaneous Lesions of Behcet's Disease | p. 329 |
Dilsen's Pathergy Test in Behcet's Disease: Positive Correlation with Clinical Manifestations | p. 331 |
Is Behcet's Disease a Kobner Positive Disorder? | p. 333 |
Extensive Pyoderma Gangrenosum-Like Lesion in Two Cases of Behcet's Disease, Responding only to Cyclosporin | p. 337 |
A Case of SAPHO Syndrome with Pyoderma Gangrenosum and Inflammatory Bowel Disease Masquerading as Behcet's Disease | p. 339 |
Cytokine Expression Within Mucocutaneous Lesions of Behcet's Disease: Involvement of Proinflammatory and Th1 Cytokines | p. 343 |
Ocular Manifestations | |
Origin and Outcome of Macular Edema in Behcet's Disease | p. 349 |
Fluorescein Angiography and Optical Coherence Tomography in Ocular Behcet's Disease | p. 355 |
Cells of the Vitreous Body in Behcet's Disease | p. 361 |
Ocular Lesions Other than Behcet's Disease in Behcet's Disease-Affected Patients | p. 365 |
Neurological manifestations | |
Neuro-Behcet's Disease (Isolated Cerebral Thrombophlebitis Excluded) | p. 371 |
The Prevalence of Headache in Behcet's Syndrome | p. 377 |
Adamantiades-Behcet's Disease and Elevated Intracranial Pressure in a 12 Year Old Turkish Girl | p. 381 |
Sensory Symptoms in Behcet's Syndrome | p. 383 |
Immunohistological Studies in Neuro-Behcet's Disease | p. 385 |
Soluble Fas Ligand Levels In Cerebrospinal Fluid in Neuro-Behcet's Disease | p. 389 |
Cardiovascular Involvement | |
Behcet's Disease With Vascular Involvement: The Contribution of Anticardiolipin Antibodies and Thrombomodulin | p. 395 |
Arterial Wall Characteristics in Patients with Adamantiades-Behcet's Disease | p. 399 |
The Influence of Plasma Fibrinogen and Serum Ferrum on Blood Viscosity in Adamantiades-Behcet's Disease | p. 405 |
Does Hyperhomocysteinemia Increase the Risk of Thrombosis in Behcet's Disease? | p. 413 |
Pulmonary Artery Involvement in Behcet's Disease | p. 419 |
Cardiac Manifestation in Four Patients with Adamantiades-Behcet's Disease | p. 423 |
Quantitative Evaluation of Microvessels in Behcet's Disease | p. 427 |
[superscript 18]F-FDG-Positron Emission Tomography for Diagnosis of Large Vessel Arteritis in Behcet's Disease | p. 435 |
Spontaneous Platelet Aggregation in Patients with Behcet's Disease by Using Laser-Light Scattering Aggregometer | p. 437 |
Various Clinical Manifestations | |
New Perspectives of Imaging Techniques for Diagnosis of Organ Manifestations in Behcet's Disease | p. 445 |
The Comparison of Ankylosing Spondylitis in Behcet's Disease and Normal Population | p. 449 |
Gastro-Intestinal Manifestations of Behcet's Disease | p. 455 |
Gastrointestinal Disease in Behcet's Disease | p. 459 |
Clinical Features of Behcet's Disease Patients with Epididymitis | p. 465 |
Tonsillectomy and Behcet's Disease | p. 471 |
Destructive Sinusopathy and Middle Ear Involvement in Behcet's Syndrome | p. 473 |
Urine Abnormalities in Behcet's Disease | p. 477 |
Treatment | |
Behcet's Syndrome: From Aetiology to Treatment | p. 481 |
Treatment of Ocular Manifestations of Behcet's Disease | p. 487 |
The Influence of the Delay of Aggressive Treatment on the Vision and its Outcome in Behcet's Disease | p. 493 |
The Clinical Outcome and Treatment in Behcet's Disease with Deep Vein Thrombosis | p. 495 |
The Use of Interferon-[alpha] in Behcet's Disease--Review of the Literature and Possible Mechanisms of Action | p. 503 |
Interferon alfa-2a in the Treatment of Ocular Adamantiades-Behcet's Disease | p. 511 |
Human Recombinant Interferon-[alpha]2a (rhIFN[alpha]2a) for the Treatment of Behcet's Disease with Sight-Threatening Retinal Vasculitis | p. 521 |
Behcet's Disease: Visual Acuity after 5 Years in Patients with alpha-Interferon Treatment | p. 525 |
Multifocal ERG Changes in Patients with Ocular Behcet's Disease During Therapy with Interferon alpha 2a | p. 529 |
Influence of Interferon-alpha on Lymphocyte Subpopulations in Behcet's Disease | p. 533 |
Interferon alpha 2a in IRPB-Derived Peptide-Induced EAU--Part I | p. 537 |
A Case of Behcet's Disease with Pathergy Reaction at Interferon Injection Site | p. 541 |
Current and Future Use of Anti-TNF Agents in the Treatment of Autoimmune, Inflammatory Disorders | p. 545 |
Successful Long-Term Treatment of Refractory Adamantiades-Behcet's Disease (ABD) with Infliximab: Report of Two Patients | p. 551 |
The Effect of Anti-Tumour Necrosis Factor Alpha (Infliximab) on Sight-Threatening Uveitis in a Patient with Behcet's Disease | p. 557 |
Antitumor Necrosis Factor Monoclonal Antibody Therapy in a Woman with Severe Adamantiades-Behcet's Disease | p. 561 |
Efficacy of Corticosteroids and Cyclosporin in the Treatment of Retinal Vasculitis in Patients with Behcet's Disease | p. 563 |
Enhancement of Transmucosal Permeation of Cyclosporine by Benzalkonium Chloride | p. 567 |
Azathioprine and Low Dose Pulse Cyclophospha-Mide in Severe Ocular Lesions of Behcet's Disease | p. 571 |
Low Dose MTX for Progressive Neuro-Behcet's Disease | p. 575 |
High Dose Methotrexate for Ocular Lesions of Behcet's Disease | p. 579 |
Therapeutic Effect of Thalidomide through Cytokine and Chemokine Regulation in Herpes Simplex Virus-Induced Behcet's Disease-Like Animal Model | p. 585 |
Pentoxifylline Use for Behcet's Disease | p. 591 |
Cataract Surgery in Behcet's Disease Patients | p. 595 |
Do Metal Surgical Staples Induce Post-Surgical Intestinal Ulcer in Behcet's Disease? | p. 599 |
Patient--Physician Relationship | |
Clinicans, Scientists and Patients | p. 603 |
Hopes of Patients with Behcet's Disease in Japan towards Researchers and the Relationship between Patients and Medical Staff Concerning Social Work | p. 605 |
Jordan Friends of Behcet's Disease Patients Society | p. 609 |
The Relationship between Patient Groups and Physicians from a UK Support Group Perspective | p. 613 |
"Living With Behcet"--A Young Patients' Group | p. 619 |
Private Practice Offices Serve as Centers for Adamantiades-Behcet's Disease | p. 621 |
The Editor | p. 627 |
Index | p. 629 |
Table of Contents provided by Rittenhouse. All Rights Reserved. |